Recognized causes of a prolonged thrombin clotting time (TCT) include a decreased plasma fibrinogen level, dysfibrinogenemia, paraproteinemia, heparin contamination, elevated levels of fibrin degradation products, and liver failure. We have frequently seen patients with an isolated prolonged TCT in the absence of any of these conditions and without obvious clinical impact. During a previous evaluation of hyperfibrinogenemia, we noted a surprisingly high incidence of prolonged TCT, prompting this evaluation of hyperfibrinogenemia as a possible cause. In our prospective study nine patients had a TCT more than 3 seconds longer than a matched control subject's TCT, with simultaneously normal prothrombin and activated partial thromboplastin times. Eight patients had fibrinogen levels more than 100 mg/dl above the control level (range 383 to 1,223 mg/dl). Only one patient's prolonged TCT could be explained on the basis of elevated levels of fibrin degradation products. In vitro studies in both a purified fibrinogen system and in plasma confirmed a delay in TCT with increasing initial fibrinogen concentrations. Kinetic measurements demonstrated a slowing of the normal initial increase in turbidity seen upon the addition of thrombin. Possible explanations include binding of thrombin to fibrin, or interference with fibrin assembly by excess fibrinogen. Regardless of the kinetic explanation, isolated prolongations of TCT due to hyperfibrinogenemia appear to be of minimal clinical significance.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/00007611-198605000-00011 | DOI Listing |
Transplant Cell Ther
January 2025
Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.
Background: While immune effector cell-associated neurotoxicity syndrome (ICANS) is a well-defined adverse effect associated with chimeric antigen receptor-modified T cell (CAR-T) therapy, some patients develop prolonged neurologic symptoms. Few studies have examined characteristics and outcomes of patients who develop such symptoms.
Objective: To provide an analysis of patients who developed ICANS in a single-center cohort of patients with large B-cell lymphoma (LBCL) who received commercial CAR-T and compare characteristics and outcomes between patients with vs.
Transplant Cell Ther
January 2025
The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address:
Transplant Cell Ther
January 2025
Azienda Sanitaria Universitaria Friuli Centrale, DMED, University of Udine, Udine, Italy.
Transplant Cell Ther
November 2024
Department of Cancer Pharmacology & Pharmacogenomics, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina.
Malignancy is a well-known risk factor for venous thromboembolism (VTE), and the Khorana risk score is effective for screening patients with solid tumors. However, there is a lack of validated screening tools and established risk factors for patients undergoing hematopoietic stem cell transplantation (HCT). Current literature reports a 2.
View Article and Find Full Text PDFTransplant Cell Ther
January 2025
Department of Medicine, Weill Cornell Medical College, New York, New York; Department of Medicine, Infectious Disease Service, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address:
Patients undergoing CD19 chimeric antigen receptor (CAR)-T cell therapy exhibit multiple immune deficits that may increase their susceptibility to infections. Invasive fungal infections (IFIs) are life-threatening events in the setting of hematologic diseases. However, there is ongoing debate regarding the optimal role and duration of antifungal prophylaxis in this specific patient population.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!